Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application
Portfolio Pulse from Lara Goldstein
Terran Biosciences has filed a patent application for solid forms of 4-OH-DiPT hemiglutarate, a psychedelic compound, amidst an ongoing court battle between Reunion Neuroscience (NASDAQ:REUN) and Mindset Pharma (OTC:MSSTF) over similar claims. Terran's application claims priority back to six provisional applications, including four filed just a week after the broad nature of RE104, Reunion's lead drug candidate, was disclosed.
July 19, 2023 | 12:47 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mindset Pharma's ongoing court battle with Reunion Neuroscience over 4-OH-DiPT prodrug patents could be further complicated by Terran Biosciences' new patent application.
The ongoing legal dispute between Mindset Pharma and Reunion Neuroscience over 4-OH-DiPT prodrug patents could be further complicated by Terran Biosciences' new patent application. This could potentially delay Mindset's operations and negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Reunion Neuroscience's ongoing court battle with Mindset Pharma over 4-OH-DiPT prodrug patents could be further complicated by Terran Biosciences' new patent application.
The ongoing legal dispute between Reunion Neuroscience and Mindset Pharma over 4-OH-DiPT prodrug patents could be further complicated by Terran Biosciences' new patent application. This could potentially delay Reunion's operations and negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100